Identification

Name
Ropinirole
Accession Number
DB00268  (APRD00302)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ropinirole is a non-ergoline dopamine agonist, manufactured by GlaxoSmithKline. It is used in the treatment of Parkinson's disease, and is also one of two medications in the United States with an FDA-approved indication for the treatment of restless legs syndrome (the other being Pramipexole).

Structure
Thumb
Synonyms
  • Ropinirol
  • Ropinirolum
External IDs
SK&F 101468 / SK&F-101468
Product Ingredients
IngredientUNIICASInChI Key
Ropinirole HydrochlorideD7ZD41RZI991374-20-8XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act RopiniroleTablet0.25 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet5 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet1 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Act RopiniroleTablet2 mgOralActavis Pharma Company2009-07-22Not applicableCanada
Dom-ropiniroleTablet0.25 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet2.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet0.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet5.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-ropiniroleTablet1.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Jamp-ropiniroleTablet1.0 mgOralJamp Pharma Corporation2010-06-16Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ropiniroleTablet4.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet0.25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet2.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet5.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet0.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet3.0 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-ropiniroleTablet1.0 mgOralApotex CorporationNot applicableNot applicableCanada
RopiniroleTablet, film coated4 mg/1OralA S Medication Solutions2010-02-252017-06-20Us
RopiniroleTablet, film coated1 mg/1OralHeritage2009-09-18Not applicableUs
RopiniroleTablet, film coated1 mg/1OralAmerincan Health Packaging2017-10-01Not applicableUs
International/Other Brands
Adartrel / ReQuip CR (GlaxoSmithKline) / Ronirol
Categories
UNII
030PYR8953
CAS number
91374-21-9
Weight
Average: 260.3746
Monoisotopic: 260.1888634
Chemical Formula
C16H24N2O
InChI Key
UHSKFQJFRQCDBE-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
IUPAC Name
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one
SMILES
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1

Pharmacology

Indication

For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.

Structured Indications
Pharmacodynamics

Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.

Mechanism of action

Ropinirole binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

TargetActionsOrganism
AD(3) dopamine receptor
agonist
Human
AD(2) dopamine receptor
agonist
Human
UD(4) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1A
agonist
Human
U5-hydroxytryptamine receptor 1D
agonist
Human
U5-hydroxytryptamine receptor 2B
agonist
Human
UD(1A) dopamine receptor
agonist
Human
UD(1B) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1B
agonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
UAlpha-2A adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
Absorption

Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.

Volume of distribution
  • 7.5 L/kg
  • 525 L
Protein binding

40% bound to plasma proteins with a blood-to-plasma ratio of 1:1.

Metabolism

Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%).

Route of elimination

Ropinirole is extensively metabolized by the liver to inactive metabolites, and less than 10% of the administered dose is excreted as unchanged drug in urine.

Half life

6 hours

Clearance
  • 47 L/hr [after oral administration to Parkinson's disease patients and patients with Restless Legs Syndrome]
Toxicity

Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ropinirole.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Ropinirole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Ropinirole can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Ropinirole can be increased when it is combined with Abiraterone.Approved
AcebutololRopinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ropinirole.Approved
AcepromazineAcepromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Ropinirole.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ropinirole.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Ropinirole.Approved
AdipiplonAdipiplon may increase the sedative activities of Ropinirole.Investigational
AgomelatineAgomelatine may increase the sedative activities of Ropinirole.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Ropinirole.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ropinirole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Aldesleukin.Approved
AlfaxaloneAlfaxalone may increase the sedative activities of Ropinirole.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Ropinirole.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Ropinirole is combined with Aliskiren.Approved, Investigational
AllopregnanoloneAllopregnanolone may increase the sedative activities of Ropinirole.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Ropinirole.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Ropinirole.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Ropinirole.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Ropinirole.Experimental, Illicit
AlphaprodineAlphaprodine may increase the sedative activities of Ropinirole.Illicit
AlprazolamAlprazolam may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
AlprenololRopinirole may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Ropinirole.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Ropinirole.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ropinirole.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ropinirole.Approved
AmiodaroneThe metabolism of Ropinirole can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the sedative activities of Ropinirole.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Ropinirole.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Ropinirole.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Ropinirole.Approved
AmperozideAmperozide may increase the sedative activities of Ropinirole.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Ropinirole.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropinirole.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ropinirole.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Ropinirole.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amyl Nitrite.Approved
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Ropinirole.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ropinirole.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Ropinirole.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Ropinirole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Ropinirole can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Ropinirole.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ropinirole.Approved, Investigational
AripiprazoleAripiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
ArotinololRopinirole may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropinirole.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Ropinirole.Approved
ArticaineArticaine may increase the sedative activities of Ropinirole.Approved
AsenapineAsenapine may increase the sedative activities of Ropinirole.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Ropinirole.Approved, Withdrawn
AtazanavirThe metabolism of Ropinirole can be decreased when combined with Atazanavir.Approved, Investigational
AtenololRopinirole may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Ropinirole can be decreased when combined with Atomoxetine.Approved
AV650The metabolism of AV650 can be decreased when combined with Ropinirole.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Ropinirole.Approved, Investigational
AzaperoneAzaperone may increase the sedative activities of Ropinirole.Vet Approved
AzelastineAzelastine may increase the sedative activities of Ropinirole.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Ropinirole can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the sedative activities of Ropinirole.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Ropinirole.Experimental
BarbitalBarbital may increase the sedative activities of Ropinirole.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ropinirole.Approved
BefunololRopinirole may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril.Approved, Investigational
BendamustineThe metabolism of Bendamustine can be decreased when combined with Ropinirole.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bendroflumethiazide.Approved
BenmoxinThe metabolism of Ropinirole can be decreased when combined with Benmoxin.Withdrawn
BenperidolBenperidol may increase the sedative activities of Ropinirole.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Ropinirole.Approved
BenzocaineBenzocaine may increase the sedative activities of Ropinirole.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Ropinirole.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Ropinirole.Approved, Withdrawn
BetaxololRopinirole may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololRopinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololRopinirole may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BlonanserinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Blonanserin.Approved
BoceprevirThe metabolism of Ropinirole can be decreased when combined with Boceprevir.Withdrawn
BopindololRopinirole may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Ropinirole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ropinirole can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bretylium.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Ropinirole.Approved
BrimonidineBrimonidine may increase the sedative activities of Ropinirole.Approved
BrofaromineThe metabolism of Ropinirole can be decreased when combined with Brofaromine.Experimental
BromazepamBromazepam may increase the sedative activities of Ropinirole.Approved, Illicit
BromisovalBromisoval may increase the sedative activities of Ropinirole.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropinirole.Approved, Investigational
BromperidolBromperidol may increase the sedative activities of Ropinirole.Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Ropinirole.Approved
BrotizolamBrotizolam may increase the sedative activities of Ropinirole.Approved, Withdrawn
BucindololRopinirole may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolRopinirole may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bumetanide.Approved
BupivacaineBupivacaine may increase the sedative activities of Ropinirole.Approved, Investigational
BupranololRopinirole may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineBuprenorphine may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bupropion.Approved
BuspironeBuspirone may increase the sedative activities of Ropinirole.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Ropinirole.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Ropinirole.Vet Approved
ButalbitalButalbital may increase the sedative activities of Ropinirole.Approved, Illicit
ButambenButamben may increase the sedative activities of Ropinirole.Approved
ButethalButethal may increase the sedative activities of Ropinirole.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Ropinirole.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the vasoconstricting activities of Ropinirole.Approved
CaffeineThe metabolism of Ropinirole can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Candesartan.Approved
CanertinibCanertinib may increase the sedative activities of Ropinirole.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Ropinirole.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Ropinirole.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropinirole.Approved
CarbinoxamineCarbinoxamine may increase the sedative activities of Ropinirole.Approved
CarfentanilCarfentanil may increase the sedative activities of Ropinirole.Illicit, Vet Approved
CariprazineThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Ropinirole.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Ropinirole.Approved
CaroxazoneThe metabolism of Ropinirole can be decreased when combined with Caroxazone.Withdrawn
CarteololRopinirole may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolRopinirole may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololRopinirole may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Ropinirole.Approved, Vet Approved
CeritinibThe serum concentration of Ropinirole can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the sedative activities of Ropinirole.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Ropinirole.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Ropinirole.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Ropinirole.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Ropinirole.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Ropinirole.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Ropinirole.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Ropinirole can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorphenamineChlorphenamine may increase the sedative activities of Ropinirole.Approved
ChlorpromazineChlorpromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Ropinirole.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Ropinirole.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropinirole.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Ropinirole.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ropinirole.Approved
CinchocaineCinchocaine may increase the sedative activities of Ropinirole.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ropinirole.Approved
CiprofloxacinThe serum concentration of Ropinirole can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Ropinirole.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Ropinirole can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ropinirole can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the sedative activities of Ropinirole.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Ropinirole.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Ropinirole.Approved
ClidiniumClidinium may increase the sedative activities of Ropinirole.Approved
ClobazamClobazam may increase the sedative activities of Ropinirole.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Ropinirole.Approved, Investigational
clomethiazoleclomethiazole may increase the sedative activities of Ropinirole.Investigational
ClomipramineClomipramine may increase the sedative activities of Ropinirole.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Ropinirole.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Ropinirole.Approved
ClopenthixolClopenthixol may increase the sedative activities of Ropinirole.Experimental
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ropinirole.Approved, Nutraceutical
CloranololRopinirole may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateClorazepate may increase the sedative activities of Ropinirole.Approved, Illicit
ClothiapineClothiapine may increase the sedative activities of Ropinirole.Experimental
ClotrimazoleThe metabolism of Ropinirole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the sedative activities of Ropinirole.Approved
CobicistatThe metabolism of Ropinirole can be decreased when combined with Cobicistat.Approved
CocaineCocaine may increase the sedative activities of Ropinirole.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ropinirole.Approved, Illicit
ConivaptanThe serum concentration of Ropinirole can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Ropinirole can be increased when it is combined with Conjugated estrogens.Approved
CrizotinibThe metabolism of Ropinirole can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the sedative activities of Ropinirole.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Ropinirole.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Ropinirole.Approved, Investigational
CyclosporineThe metabolism of Ropinirole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the sedative activities of Ropinirole.Approved
Cyproterone acetateThe serum concentration of Ropinirole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ropinirole can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Ropinirole.Approved, Investigational
DaidzeinThe serum concentration of Ropinirole can be increased when it is combined with Daidzein.Experimental
DantroleneDantrolene may increase the sedative activities of Ropinirole.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Ropinirole.Approved
DapiprazoleDapiprazole may increase the sedative activities of Ropinirole.Approved
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Ropinirole.Approved, Investigational
DarunavirThe metabolism of Ropinirole can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Ropinirole.Approved
DasatinibThe serum concentration of Ropinirole can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Ropinirole.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Ropinirole.Approved
DeferasiroxThe serum concentration of Ropinirole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ropinirole can be decreased when combined with Delavirdine.Approved
DeramciclaneDeramciclane may increase the sedative activities of Ropinirole.Investigational
DesfluraneDesflurane may increase the sedative activities of Ropinirole.Approved
DesipramineDesipramine may increase the sedative activities of Ropinirole.Approved
DesloratadineDesloratadine may increase the sedative activities of Ropinirole.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Ropinirole.Approved
DetomidineDetomidine may increase the sedative activities of Ropinirole.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Ropinirole.Approved, Investigational
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Ropinirole.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Ropinirole.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ropinirole.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the sedative activities of Ropinirole.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Ropinirole.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Ropinirole.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ropinirole.Approved
DextromoramideDextromoramide may increase the sedative activities of Ropinirole.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
DezocineDezocine may increase the sedative activities of Ropinirole.Approved
DiazepamDiazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Ropinirole.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ropinirole.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Ropinirole can be increased when it is combined with Dienestrol.Approved
Diethyl etherDiethyl ether may increase the sedative activities of Ropinirole.Experimental
DiethylstilbestrolThe serum concentration of Ropinirole can be increased when it is combined with Diethylstilbestrol.Approved
DifenoxinDifenoxin may increase the sedative activities of Ropinirole.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the sedative activities of Ropinirole.Approved, Illicit
DihydroergotamineThe metabolism of Ropinirole can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the sedative activities of Ropinirole.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Ropinirole.Experimental, Illicit
DiltiazemThe metabolism of Ropinirole can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Ropinirole.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Ropinirole.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Ropinirole.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Ropinirole.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dipyridamole.Approved
DixyrazineDixyrazine may increase the sedative activities of Ropinirole.Experimental
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ropinirole.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Ropinirole.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Ropinirole.Approved
DoramectinDoramectin may increase the sedative activities of Ropinirole.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Ropinirole.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Ropinirole.Approved
DoxepinDoxepin may increase the sedative activities of Ropinirole.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ropinirole.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Ropinirole.Approved, Investigational
DoxycyclineThe metabolism of Ropinirole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the sedative activities of Ropinirole.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Ropinirole.Investigational
DronedaroneThe metabolism of Ropinirole can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the sedative activities of Ropinirole.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Ropinirole.Experimental, Illicit
DroxidopaRopinirole may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineRopinirole may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Ropinirole.Approved
EcgonineEcgonine may increase the sedative activities of Ropinirole.Experimental, Illicit
EcopipamEcopipam may increase the sedative activities of Ropinirole.Investigational
EfavirenzEfavirenz may increase the sedative activities of Ropinirole.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropinirole.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Ropinirole.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ropinirole.Approved
EltanoloneEltanolone may increase the sedative activities of Ropinirole.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Ropinirole.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Ropinirole.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Ropinirole.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Ropinirole.Investigational
EnfluraneEnflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Ropinirole.Approved, Investigational
EnzalutamideThe serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide.Approved
EpanololRopinirole may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EpimestrolThe serum concentration of Ropinirole can be increased when it is combined with Epimestrol.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Ropinirole.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropinirole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Eprosartan.Approved
EquolThe serum concentration of Ropinirole can be increased when it is combined with Equol.Investigational
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Ropinirole.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Ropinirole.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Ropinirole.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Ropinirole.Approved, Investigational
ErythromycinThe metabolism of Ropinirole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Ropinirole.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Ropinirole.Investigational
EsmololRopinirole may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamEstazolam may increase the sedative activities of Ropinirole.Approved, Illicit
EstradiolThe serum concentration of Ropinirole can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Ropinirole can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Ropinirole can be increased when it is combined with Estrone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ropinirole.Approved
EszopicloneEszopiclone may increase the sedative activities of Ropinirole.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Ropinirole is combined with Etacrynic acid.Approved
EthanolEthanol may increase the sedative activities of Ropinirole.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ropinirole can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideEthosuximide may increase the sedative activities of Ropinirole.Approved
EthotoinEthotoin may increase the sedative activities of Ropinirole.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Ropinirole.Withdrawn
Ethyl chlorideEthyl chloride may increase the sedative activities of Ropinirole.Experimental
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Ropinirole.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Ropinirole.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Ropinirole.Approved
EtifoxineEtifoxine may increase the sedative activities of Ropinirole.Withdrawn
EtizolamEtizolam may increase the sedative activities of Ropinirole.Approved
EtomidateEtomidate may increase the sedative activities of Ropinirole.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Ropinirole.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ropinirole.Approved, Investigational
EtorphineEtorphine may increase the sedative activities of Ropinirole.Illicit, Vet Approved
EzogabineEzogabine may increase the sedative activities of Ropinirole.Approved
FelbamateFelbamate may increase the sedative activities of Ropinirole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropinirole.Approved
FentanylFentanyl may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.Approved
FexofenadineFexofenadine may increase the sedative activities of Ropinirole.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ropinirole.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Ropinirole.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Ropinirole.Approved, Withdrawn
FlibanserinFlibanserin may increase the sedative activities of Ropinirole.Approved
FluanisoneFluanisone may increase the sedative activities of Ropinirole.Experimental
FluconazoleThe metabolism of Ropinirole can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the sedative activities of Ropinirole.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Ropinirole.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Ropinirole.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Ropinirole.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Ropinirole.Approved, Vet Approved
FlupentixolFlupentixol may increase the sedative activities of Ropinirole.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Ropinirole.Approved
FlurazepamFlurazepam may increase the sedative activities of Ropinirole.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Ropinirole.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Ropinirole.Approved
Fluticasone propionateFluticasone propionate may increase the sedative activities of Ropinirole.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ropinirole.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Ropinirole.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Ropinirole.Approved, Investigational
FosamprenavirThe metabolism of Ropinirole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ropinirole can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Ropinirole.Approved
FospropofolFospropofol may increase the sedative activities of Ropinirole.Approved, Illicit
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Ropinirole.Approved, Investigational
FurazolidoneThe metabolism of Ropinirole can be decreased when combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ropinirole can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the sedative activities of Ropinirole.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the sedative activities of Ropinirole.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Ropinirole.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Ropinirole.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Ropinirole.Approved, Investigational
GenisteinThe serum concentration of Ropinirole can be increased when it is combined with Genistein.Investigational
GepironeGepirone may increase the sedative activities of Ropinirole.Investigational
GlutethimideGlutethimide may increase the sedative activities of Ropinirole.Approved, Illicit
GranisetronThe metabolism of Granisetron can be decreased when combined with Ropinirole.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Ropinirole.Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Ropinirole.Approved
GuanfacineGuanfacine may increase the sedative activities of Ropinirole.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Ropinirole.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Ropinirole.Approved
HaloperidolHaloperidol may increase the sedative activities of Ropinirole.Approved
HalothaneHalothane may increase the sedative activities of Ropinirole.Approved, Vet Approved
HarmalineThe metabolism of Ropinirole can be decreased when combined with Harmaline.Experimental
HeroinHeroin may increase the sedative activities of Ropinirole.Approved, Illicit
HesperetinThe metabolism of Hesperetin can be decreased when combined with Ropinirole.Approved
HexestrolThe serum concentration of Ropinirole can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalHexobarbital may increase the sedative activities of Ropinirole.Approved
HydracarbazineThe metabolism of Ropinirole can be decreased when combined with Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Ropinirole.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropinirole.Approved
HydromorphoneHydromorphone may increase the sedative activities of Ropinirole.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Ropinirole.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Ropinirole.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Ropinirole.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ropinirole.Approved
IdelalisibThe serum concentration of Ropinirole can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the sedative activities of Ropinirole.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropinirole.Approved, Investigational
ImatinibThe metabolism of Ropinirole can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropinirole.Investigational
ImipramineImipramine may increase the sedative activities of Ropinirole.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ropinirole.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.Approved
IndenololRopinirole may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Ropinirole can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the sedative activities of Ropinirole.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropinirole.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Ropinirole.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Ropinirole.Approved
IprindoleIprindole may decrease the antihypertensive activities of Ropinirole.Experimental
IproclozideThe metabolism of Ropinirole can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Ropinirole can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Ropinirole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropinirole.Approved
IsofluraneIsoflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ropinirole can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ropinirole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ropinirole can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ropinirole.Approved
KetamineKetamine may increase the sedative activities of Ropinirole.Approved, Vet Approved
KetazolamKetazolam may increase the sedative activities of Ropinirole.Approved
KetobemidoneKetobemidone may increase the sedative activities of Ropinirole.Approved
KetoconazoleThe metabolism of Ropinirole can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolRopinirole may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ropinirole.Approved
LamotrigineLamotrigine may increase the sedative activities of Ropinirole.Approved, Investigational
LandiololRopinirole may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Ropinirole.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropinirole.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Ropinirole.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Ropinirole is combined with Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the sedative activities of Ropinirole.Approved
LevocabastineLevocabastine may increase the sedative activities of Ropinirole.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Ropinirole.Approved
LevodopaLevodopa may increase the sedative activities of Ropinirole.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Ropinirole.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Ropinirole.Approved
LevorphanolLevorphanol may increase the sedative activities of Ropinirole.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Ropinirole.Approved, Investigational
LidocaineLidocaine may increase the sedative activities of Ropinirole.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Ropinirole.Approved
LithiumLithium may increase the sedative activities of Ropinirole.Approved
LobeglitazoneThe metabolism of Ropinirole can be decreased when combined with Lobeglitazone.Approved
LofentanilLofentanil may increase the sedative activities of Ropinirole.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Ropinirole.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Ropinirole.Approved, Investigational
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Ropinirole.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Ropinirole.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Ropinirole.Approved
LopinavirThe metabolism of Ropinirole can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the sedative activities of Ropinirole.Experimental
LoratadineLoratadine may increase the sedative activities of Ropinirole.Approved
LorazepamLorazepam may increase the sedative activities of Ropinirole.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ropinirole.Approved
LormetazepamLormetazepam may increase the sedative activities of Ropinirole.Approved
LosartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.Approved
LovastatinThe metabolism of Ropinirole can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the sedative activities of Ropinirole.Approved
LuliconazoleThe serum concentration of Ropinirole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ropinirole can be increased when combined with Lumacaftor.Approved
LumateperoneThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Lumateperone.Investigational
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Ropinirole.Approved, Investigational
LurasidoneLurasidone may increase the sedative activities of Ropinirole.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Ropinirole.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Ropinirole.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Ropinirole is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Ropinirole.Approved
MebanazineThe metabolism of Ropinirole can be decreased when combined with Mebanazine.Withdrawn
MebicarMebicar may increase the sedative activities of Ropinirole.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Mecamylamine.Approved
MeclizineMeclizine may increase the sedative activities of Ropinirole.Approved
MedazepamMedazepam may increase the sedative activities of Ropinirole.Experimental
MedetomidineMedetomidine may increase the sedative activities of Ropinirole.Vet Approved
MelatoninMelatonin may increase the sedative activities of Ropinirole.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Ropinirole.Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Ropinirole.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ropinirole.Investigational, Withdrawn
MepindololRopinirole may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineMepivacaine may increase the sedative activities of Ropinirole.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Ropinirole.Approved, Illicit
MeptazinolMeptazinol may increase the sedative activities of Ropinirole.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Ropinirole.Approved
MesoridazineMesoridazine may increase the sedative activities of Ropinirole.Approved
MestranolThe serum concentration of Ropinirole can be increased when it is combined with Mestranol.Approved
MetaxaloneMetaxalone may increase the sedative activities of Ropinirole.Approved
MethadoneMethadone may increase the sedative activities of Ropinirole.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Ropinirole.Approved, Illicit
MethallenestrilThe serum concentration of Ropinirole can be increased when it is combined with Methallenestril.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Ropinirole.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Ropinirole.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Ropinirole.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the sedative activities of Ropinirole.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Ropinirole.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Ropinirole.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Ropinirole.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Ropinirole is combined with Methyldopa.Approved
MethylecgonineMethylecgonine may increase the sedative activities of Ropinirole.Experimental
Methylene blueThe metabolism of Ropinirole can be decreased when combined with Methylene blue.Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Ropinirole.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Ropinirole.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Ropinirole.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Ropinirole is combined with Metipranolol.Approved
MetoclopramideThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ropinirole.Approved, Investigational
MexiletineThe metabolism of Ropinirole can be decreased when combined with Mexiletine.Approved
MianserinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Mianserin.Approved
MidazolamMidazolam may increase the sedative activities of Ropinirole.Approved, Illicit
MidostaurinThe metabolism of Ropinirole can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ropinirole can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may decrease the antihypertensive activities of Ropinirole.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Ropinirole.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Ropinirole.Approved
MitotaneThe serum concentration of Ropinirole can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Moexipril.Approved
MolindoneMolindone may increase the sedative activities of Ropinirole.Approved
MorphineMorphine may increase the sedative activities of Ropinirole.Approved, Investigational
MoxestrolThe serum concentration of Ropinirole can be increased when it is combined with Moxestrol.Experimental
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Ropinirole.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Ropinirole.Investigational
NabiloneNabilone may increase the sedative activities of Ropinirole.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Ropinirole.Approved
NadololRopinirole may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineNalbuphine may increase the sedative activities of Ropinirole.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Ropinirole.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ropinirole.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ropinirole.Approved, Investigational
NefazodoneThe metabolism of Ropinirole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ropinirole can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Ropinirole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ropinirole can be increased when combined with Nevirapine.Approved
NialamideThe metabolism of Ropinirole can be decreased when combined with Nialamide.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Ropinirole.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Ropinirole.Approved
NicorandilNicorandil may increase the hypotensive activities of Ropinirole.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Ropinirole.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Ropinirole.Approved
NilotinibThe metabolism of Ropinirole can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropinirole.Approved
NimodipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nisoldipine.Approved
NitrazepamNitrazepam may increase the sedative activities of Ropinirole.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Ropinirole.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Ropinirole.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroprusside.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Ropinirole.Approved, Vet Approved
NorfluraneNorflurane may increase the sedative activities of Ropinirole.Investigational
NormethadoneNormethadone may increase the sedative activities of Ropinirole.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Ropinirole.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropinirole.Approved
OctamoxinThe metabolism of Ropinirole can be decreased when combined with Octamoxin.Withdrawn
OlanzapineOlanzapine may increase the sedative activities of Ropinirole.Approved, Investigational
OlaparibThe metabolism of Ropinirole can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Ropinirole.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the sedative activities of Ropinirole.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Ropinirole.Investigational
OpiumOpium may increase the sedative activities of Ropinirole.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Ropinirole.Approved
OsanetantOsanetant may increase the sedative activities of Ropinirole.Investigational
OsimertinibThe serum concentration of Ropinirole can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Ropinirole.Approved, Investigational
OxazepamOxazepam may increase the sedative activities of Ropinirole.Approved
OxethazaineOxethazaine may increase the sedative activities of Ropinirole.Investigational
OxprenololOxprenolol may increase the sedative activities of Ropinirole.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Ropinirole.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Ropinirole.Approved
OxycodoneOxycodone may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropinirole.Approved, Vet Approved
PalbociclibThe serum concentration of Ropinirole can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the sedative activities of Ropinirole.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Ropinirole.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Ropinirole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.Approved
ParaldehydeParaldehyde may increase the sedative activities of Ropinirole.Approved
PargylineThe metabolism of Ropinirole can be decreased when combined with Pargyline.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Ropinirole.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Ropinirole.Approved
Peginterferon alfa-2bThe serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololRopinirole may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may increase the sedative activities of Ropinirole.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Ropinirole.Approved
PentazocinePentazocine may increase the sedative activities of Ropinirole.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Ropinirole.Approved, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Ropinirole.Approved, Investigational
PerampanelPerampanel may increase the sedative activities of Ropinirole.Approved
PerazinePerazine may increase the sedative activities of Ropinirole.Investigational
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Ropinirole.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Perindopril.Approved
PerospironePerospirone may increase the sedative activities of Ropinirole.Approved
PerphenazinePerphenazine may increase the sedative activities of Ropinirole.Approved
PethidinePethidine may increase the sedative activities of Ropinirole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ropinirole.Withdrawn
PhenazocinePhenazocine may increase the sedative activities of Ropinirole.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ropinirole.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Ropinirole.Approved, Withdrawn
PhenibutPhenibut may increase the sedative activities of Ropinirole.Experimental
PheniprazineThe metabolism of Ropinirole can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the sedative activities of Ropinirole.Approved
PhenoperidinePhenoperidine may increase the sedative activities of Ropinirole.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropinirole.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Ropinirole.Approved
PhenoxypropazineThe metabolism of Ropinirole can be decreased when combined with Phenoxypropazine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Ropinirole.Approved
PhenytoinPhenytoin may increase the sedative activities of Ropinirole.Approved, Vet Approved
PimavanserinThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Pimavanserin.Investigational
PimozidePimozide may increase the sedative activities of Ropinirole.Approved
PindololRopinirole may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperonePipamperone may increase the sedative activities of Ropinirole.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Ropinirole.Approved, Vet Approved
PipotiazinePipotiazine may increase the sedative activities of Ropinirole.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Ropinirole.Investigational
PiritramidePiritramide may increase the sedative activities of Ropinirole.Investigational
PirlindoleThe metabolism of Ropinirole can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Ropinirole can be decreased when combined with Pivhydrazine.Withdrawn
PizotifenPizotifen may increase the sedative activities of Ropinirole.Approved
Polyestradiol phosphateThe serum concentration of Ropinirole can be increased when it is combined with Polyestradiol phosphate.Approved
PomalidomidePomalidomide may increase the sedative activities of Ropinirole.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Ropinirole.Approved
PosaconazoleThe metabolism of Ropinirole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololRopinirole may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Ropinirole.Approved, Investigational
PramocainePramocaine may increase the sedative activities of Ropinirole.Approved
PrazepamPrazepam may increase the sedative activities of Ropinirole.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Ropinirole.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Prazosin.Approved
PregabalinPregabalin may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the sedative activities of Ropinirole.Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Ropinirole.Approved
PrimidonePrimidone may increase the sedative activities of Ropinirole.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Ropinirole.Approved
ProcaineProcaine may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ropinirole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Ropinirole.Approved
PromazinePromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
PromestrieneThe serum concentration of Ropinirole can be increased when it is combined with Promestriene.Investigational
PromethazinePromethazine may increase the sedative activities of Ropinirole.Approved
PropafenoneThe serum concentration of Ropinirole can be increased when it is combined with Propafenone.Approved
PropanididPropanidid may increase the sedative activities of Ropinirole.Experimental
ProparacaineProparacaine may increase the sedative activities of Ropinirole.Approved, Vet Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Ropinirole.Approved
PropofolPropofol may increase the sedative activities of Ropinirole.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Ropinirole.Approved
PropranololRopinirole may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the sedative activities of Ropinirole.Approved
ProxibarbalProxibarbal may increase the sedative activities of Ropinirole.Experimental
PSD502PSD502 may increase the sedative activities of Ropinirole.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Ropinirole.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Ropinirole.Approved
QuazepamQuazepam may increase the sedative activities of Ropinirole.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Ropinirole.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Quinapril.Approved, Investigational
QuinestrolThe serum concentration of Ropinirole can be increased when it is combined with Quinestrol.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Ropinirole.Approved
QuinisocaineQuinisocaine may increase the sedative activities of Ropinirole.Experimental
RacloprideRaclopride may increase the sedative activities of Ropinirole.Investigational
RamelteonRamelteon may increase the sedative activities of Ropinirole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ropinirole.Approved
RanolazineThe metabolism of Ropinirole can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ropinirole.Approved
RemifentanilRemifentanil may increase the sedative activities of Ropinirole.Approved
RemoxiprideRemoxipride may increase the sedative activities of Ropinirole.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Ropinirole.Investigational
ReserpineReserpine may increase the sedative activities of Ropinirole.Approved
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Ropinirole.Experimental, Investigational
RifabutinThe metabolism of Ropinirole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ropinirole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ropinirole can be increased when combined with Rifapentine.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Ropinirole.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Ropinirole is combined with Riociguat.Approved
RisperidoneRisperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Ropinirole.Investigational
RitonavirThe metabolism of Ropinirole can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Ropinirole.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ropinirole.Investigational, Withdrawn
RomifidineRomifidine may increase the sedative activities of Ropinirole.Vet Approved
RopivacaineRopivacaine may increase the sedative activities of Ropinirole.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Ropinirole.Approved
RP5063The therapeutic efficacy of Ropinirole can be decreased when used in combination with RP5063.Investigational
RucaparibThe metabolism of Rucaparib can be decreased when combined with Ropinirole.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Ropinirole.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Sacubitril.Approved
SafrazineThe metabolism of Ropinirole can be decreased when combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Ropinirole can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the sedative activities of Ropinirole.Approved
SecobarbitalSecobarbital may increase the sedative activities of Ropinirole.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Ropinirole can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneSepranolone may increase the sedative activities of Ropinirole.Investigational
SertindoleSertindole may increase the sedative activities of Ropinirole.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Ropinirole.Approved
SevofluraneSevoflurane may increase the sedative activities of Ropinirole.Approved, Vet Approved
SildenafilThe metabolism of Ropinirole can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ropinirole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ropinirole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Ropinirole.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Ropinirole is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the sedative activities of Ropinirole.Approved
SotalolRopinirole may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Ropinirole.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Ropinirole is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ropinirole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ropinirole can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Ropinirole is combined with Streptokinase.Approved
SufentanilSufentanil may increase the sedative activities of Ropinirole.Approved, Investigational
SulfisoxazoleThe metabolism of Ropinirole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.Approved
SultoprideSultopride may increase the sedative activities of Ropinirole.Experimental
SuvorexantSuvorexant may increase the sedative activities of Ropinirole.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Ropinirole can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Ropinirole can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Ropinirole.Withdrawn
TalinololRopinirole may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ropinirole resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Ropinirole.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Ropinirole.Investigational
TapentadolTapentadol may increase the sedative activities of Ropinirole.Approved
TasimelteonTasimelteon may increase the sedative activities of Ropinirole.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Ropinirole.Investigational, Withdrawn
TelaprevirThe metabolism of Ropinirole can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Ropinirole can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan.Approved, Investigational
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Ropinirole.Withdrawn
TemazepamTemazepam may increase the sedative activities of Ropinirole.Approved
Tenofovir disoproxilThe metabolism of Ropinirole can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ropinirole.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Ropinirole.Withdrawn
TeriflunomideThe serum concentration of Ropinirole can be decreased when it is combined with Teriflunomide.Approved
TertatololRopinirole may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Ropinirole.Investigational
TetrabenazineTetrabenazine may increase the sedative activities of Ropinirole.Approved
TetracaineTetracaine may increase the sedative activities of Ropinirole.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the sedative activities of Ropinirole.Investigational
TetrodotoxinTetrodotoxin may increase the sedative activities of Ropinirole.Investigational
ThalidomideThalidomide may increase the sedative activities of Ropinirole.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Ropinirole.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ropinirole.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Ropinirole.Approved, Vet Approved
ThiamylalThiamylal may increase the sedative activities of Ropinirole.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Ropinirole.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Ropinirole.Approved
ThioridazineThioridazine may increase the sedative activities of Ropinirole.Withdrawn
ThiothixeneThiothixene may increase the sedative activities of Ropinirole.Approved
TiagabineTiagabine may increase the sedative activities of Ropinirole.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Ropinirole.Approved
TiaprideTiapride may increase the sedative activities of Ropinirole.Approved, Investigational
TiboloneThe serum concentration of Ropinirole can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Ropinirole can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the sedative activities of Ropinirole.Vet Approved
TilidineTilidine may increase the sedative activities of Ropinirole.Experimental
TimololRopinirole may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Ropinirole.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Ropinirole.Approved, Investigational
TizanidineTizanidine may increase the sedative activities of Ropinirole.Approved
TocilizumabThe serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Ropinirole is combined with Tolazoline.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Ropinirole.Approved, Withdrawn
ToloxatoneThe metabolism of Ropinirole can be decreased when combined with Toloxatone.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Ropinirole.Approved, Investigational
TopiramateTopiramate may increase the sedative activities of Ropinirole.Approved
TorasemideThe risk or severity of adverse effects can be increased when Ropinirole is combined with Torasemide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Ropinirole.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Ropinirole.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ropinirole.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Ropinirole is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Ropinirole.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Ropinirole.Approved
TrazodoneTrazodone may increase the sedative activities of Ropinirole.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Ropinirole is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe metabolism of Triamterene can be decreased when combined with Ropinirole.Approved
TriazolamTriazolam may increase the sedative activities of Ropinirole.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the sedative activities of Ropinirole.Vet Approved
TrichloroethyleneTrichloroethylene may increase the sedative activities of Ropinirole.Experimental
TrifluoperazineTrifluoperazine may increase the sedative activities of Ropinirole.Approved
TrifluperidolTrifluperidol may increase the sedative activities of Ropinirole.Experimental
TriflupromazineTriflupromazine may increase the sedative activities of Ropinirole.Approved, Vet Approved
TrimipramineTrimipramine may increase the sedative activities of Ropinirole.Approved
TriprolidineTriprolidine may increase the sedative activities of Ropinirole.Approved
UlipristalThe metabolism of Ulipristal can be decreased when combined with Ropinirole.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Ropinirole.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Ropinirole.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Ropinirole.Approved, Investigational
Valproic AcidValproic Acid may increase the sedative activities of Ropinirole.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Ropinirole is combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Ropinirole can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ropinirole can be decreased when combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the sedative activities of Ropinirole.Experimental
VerapamilThe metabolism of Ropinirole can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Ropinirole.Approved, Investigational
VigabatrinVigabatrin may increase the sedative activities of Ropinirole.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Ropinirole.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Ropinirole.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Ropinirole.Approved, Investigational
Vinyl etherVinyl ether may increase the sedative activities of Ropinirole.Experimental
VoriconazoleThe metabolism of Ropinirole can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the sedative activities of Ropinirole.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Ropinirole.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Ropinirole.Approved
XenonXenon may increase the sedative activities of Ropinirole.Experimental
XylazineXylazine may increase the sedative activities of Ropinirole.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Ropinirole.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ropinirole.Approved
ZaleplonZaleplon may increase the sedative activities of Ropinirole.Approved, Illicit, Investigational
ZeranolThe serum concentration of Ropinirole can be increased when it is combined with Zeranol.Vet Approved
ZiconotideZiconotide may increase the sedative activities of Ropinirole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ropinirole.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may increase the sedative activities of Ropinirole.Approved
ZolazepamZolazepam may increase the sedative activities of Ropinirole.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Ropinirole.Approved, Investigational
ZolpidemZolpidem may increase the sedative activities of Ropinirole.Approved
ZonisamideZonisamide may increase the sedative activities of Ropinirole.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Ropinirole.Approved
ZotepineZotepine may increase the sedative activities of Ropinirole.Approved
ZucapsaicinThe metabolism of Ropinirole can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolZuclopenthixol may increase the sedative activities of Ropinirole.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4452808
General References
Not Available
External Links
Human Metabolome Database
HMDB14413
KEGG Drug
D08489
KEGG Compound
C07564
PubChem Compound
5095
PubChem Substance
46507918
ChemSpider
4916
BindingDB
50020680
ChEBI
8888
ChEMBL
CHEMBL589
Therapeutic Targets Database
DAP001515
PharmGKB
PA164749035
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ropinirole
ATC Codes
N04BC04 — Ropinirole
AHFS Codes
  • 28:36.20.08 — Nonergot-derivative Dopamine Receptor Agonists
FDA label
Download (267 KB)
MSDS
Download (29.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailablePharmacokinetic Study2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentParkinson's Disease (PD)1
1CompletedTreatmentRestless Legs Syndrome (RLS)2
1, 2RecruitingTreatmentParkinson's Disease (PD)1
1, 2RecruitingTreatmentIdiopathic hyperprolactinemic disorder / Prolactinoma1
2CompletedTreatmentCerebrovascular Accidents / Hemiparesis1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentFibromyalgia Syndrome, Primary1
2CompletedTreatmentParkinson's Disease (PD)1
2TerminatedTreatmentRestless Legs Syndrome (RLS)1
2Unknown StatusTreatmentUnverricht-Lundborg Syndrome1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentModerate to Severe Idiopathic Restless Legs Syndrome (RLS) / Restless Legs Syndrome (RLS)1
3CompletedTreatmentParkinson's Disease (PD)5
3CompletedTreatmentRestless Legs Syndrome (RLS)6
3Unknown StatusTreatmentParkinson's Disease (PD)1
4CompletedDiagnosticParkinson's Disease (PD)1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentParkinson's Disease (PD)1
4CompletedTreatmentRestless Legs Syndrome (RLS)1
4CompletedTreatmentSexual Dysfunctions1
4Enrolling by InvitationSupportive CareLiver Cirrhosis / Muscle Cramps1
4Unknown StatusTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableRestless Legs Syndrome (RLS)1
Not AvailableCompletedTreatmentParkinson's Disease (PD) / Restless Legs Syndrome (RLS)2
Not AvailableRecruitingNot AvailableAtypical Parkinson Disease / Corticobasal Degeneration / Gait, Frontal / Multiple System Atrophy (MSA) / Parkinson's Disease (PD) / Parkinsonian Disorders / Progressive Supranuclear Palsy (PSP)1

Pharmacoeconomics

Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Glaxosmithkline
  • Alembic ltd
  • Corepharma llc
  • Glenmark generics ltd
  • Huahai us inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
TabletOral3.0 mg
TabletOral4.0 mg
TabletOral0.5 mg
TabletOral1.0 mg
TabletOral2.0 mg
TabletOral5.0 mg
TabletOral0.25 mg
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
Tablet, film coated, extended releaseOral12 mg/1
Tablet, film coated, extended releaseOral2 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral6 mg/1
Tablet, film coated, extended releaseOral8 mg/1
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral3 mg/1
TabletOral4 mg/1
TabletOral5 mg/1
Tablet, coatedOral.25 mg/1
Tablet, coatedOral.5 mg/1
Tablet, coatedOral1 mg/1
Tablet, coatedOral2 mg/1
Tablet, coatedOral4 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral.25 mg/1
Tablet, film coatedOral.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral3 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Requip XL 12 mg 24 Hour tablet14.92USD tablet
Requip xl 12 mg tablet14.35USD tablet
Requip XL 8 mg 24 Hour tablet8.96USD tablet
Requip xl 6 mg tablet8.61USD tablet
Requip xl 8 mg tablet8.61USD tablet
Requip XL 4 mg 24 Hour tablet5.97USD tablet
Requip xl 4 mg tablet5.74USD tablet
Requip 5 mg Tablet3.87USD tablet
Requip 3 mg tablet3.41USD tablet
Requip 4 mg tablet3.41USD tablet
Requip 5 mg tablet3.41USD tablet
Requip 0.25 mg tablet3.29USD tablet
Requip 0.5 mg tablet3.29USD tablet
Requip 1 mg tablet3.29USD tablet
Requip 2 mg tablet3.29USD tablet
Requip xl 2 mg tablet2.87USD tablet
Ropinirole hcl 3 mg tablet2.65USD tablet
Ropinirole hcl 4 mg tablet2.65USD tablet
Ropinirole hcl 5 mg tablet2.65USD tablet
Ropinirole hcl 0.25 mg tablet2.55USD tablet
Ropinirole hcl 0.5 mg tablet2.55USD tablet
Ropinirole hcl 1 mg tablet2.55USD tablet
Ropinirole hcl 2 mg tablet2.55USD tablet
Co Ropinirole 5 mg Tablet1.8USD tablet
Pms-Ropinirole 5 mg Tablet1.8USD tablet
Ran-Ropinirole 5 mg Tablet1.8USD tablet
Ropinirole 5 mg Tablet1.8USD tablet
Requip 2 mg Tablet1.41USD tablet
Requip 1 mg Tablet1.28USD tablet
Co Ropinirole 2 mg Tablet0.65USD tablet
Pms-Ropinirole 2 mg Tablet0.65USD tablet
Ran-Ropinirole 2 mg Tablet0.65USD tablet
Ropinirole 2 mg Tablet0.65USD tablet
Co Ropinirole 1 mg Tablet0.59USD tablet
Pms-Ropinirole 1 mg Tablet0.59USD tablet
Ran-Ropinirole 1 mg Tablet0.59USD tablet
Ropinirole 1 mg Tablet0.59USD tablet
Requip 0.25 mg Tablet0.32USD tablet
Co Ropinirole 0.25 mg Tablet0.15USD tablet
Pms-Ropinirole 0.25 mg Tablet0.15USD tablet
Ran-Ropinirole 0.25 mg Tablet0.15USD tablet
Ropinirole 0.25 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5422123No1995-06-062012-06-06Us
US7927624No2001-12-022021-12-02Us
US8303986No2001-04-122021-04-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)243-250 °CNot Available
water solubility133 mg/mLNot Available
logP2.70ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.353 mg/mLALOGPS
logP3.16ALOGPS
logP3.06ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)13.24ChemAxon
pKa (Strongest Basic)10.17ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity81.43 m3·mol-1ChemAxon
Polarizability31.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9971
Caco-2 permeable+0.6087
P-glycoprotein substrateSubstrate0.7604
P-glycoprotein inhibitor IInhibitor0.5458
P-glycoprotein inhibitor IINon-inhibitor0.8641
Renal organic cation transporterNon-inhibitor0.602
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6903
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6959
Ames testNon AMES toxic0.7302
CarcinogenicityNon-carcinogens0.905
BiodegradationNot ready biodegradable0.9966
Rat acute toxicity2.6400 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8959
hERG inhibition (predictor II)Non-inhibitor0.7066
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0190000000-7e072cf65f341641938c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-3960000000-47d2311adfeeacf4062d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-7900000000-0891c66db163729a5360
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-88c0fa3d93090a0d06c6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-3590000000-8fb5fc766313ee6bbd9e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0k96-9400000000-f1b50dacd59a9bfe90b7

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolines
Direct Parent
Indolines
Alternative Parents
Phenethylamines / Aralkylamines / Trialkylamines / Secondary carboxylic acid amides / Lactams / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Dihydroindole / Phenethylamine / Aralkylamine / Benzenoid / Amino acid or derivatives / Carboxamide group / Lactam / Secondary carboxylic acid amide / Tertiary aliphatic amine / Tertiary amine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amine, indolones (CHEBI:8888)

Targets

Details
1. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [PubMed:1683559]
  3. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999 Aug 14;838(1-2):51-9. [PubMed:10446316]
  4. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  5. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  6. Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV: Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Res. 2007 Jul 30;1160:113-23. Epub 2007 May 26. [PubMed:17573046]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
7. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
8. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:21